| Issue Number
38,
December 2, 2005 |
| |
| Contents of this Issue |
|
|
|
ABBREVIATIONS: ACIP, Advisory Committee on Immunization Practices; CDC, Centers
for Disease Control and Prevention; DVH, Division of Viral Hepatitis; HAV,
hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; IAC,
Immunization Action Coalition; IDU, injection drug user; MMWR, Morbidity and
Mortality Weekly Report; MSM, men who have sex with men; STD, sexually
transmitted disease; VIS, Vaccine Information Statement; WHO, World Health
Organization.
----------------------------------------------------------------
(1 of 9)
December 2, 2005
VISIT IAC'S BOOTH AT THE NATIONAL VIRAL HEPATITIS PREVENTION
CONFERENCE NEXT WEEK!
IAC will be hosting a booth at the National Viral Hepatitis
Prevention Conference in Washington, DC, next week. Please stop
by and introduce yourself--we would love to meet our Hep Express
subscribers. We look forward to receiving feedback on our
electronic newsletters, websites, and resource materials. We get
some of our best ideas from our readers!
----------------------------------------------------------------
Return to top
(2 of 9)
December 2, 2005
RIBAVIRIN PREGNANCY REGISTRY ESTABLISHED
A Ribavirin Pregnancy Registry has been established to monitor pregnancy
exposures to ribavirin. The registry is a voluntary, largely prospective
registry designed to collect observational data on pregnancies and outcomes
following a pregnancy exposure to ribavirin. The registry also collects
retrospective information, i.e., reports after the outcome of the pregnancy is
known. Ribovirin exposure may be direct, through the pregnant woman or indirect,
through her male sexual partner.
Ribavirin, a nucleoside analog, is indicated in combination with alpha
interferon or pegylated alpha interferon for the treatment of chronic hepatitis
C virus infection (HCV). The incidence of HCV infection is highest in the
population with reproductive potential (25–45 years of age). Therefore, it is
possible that pregnancy exposure may occur during or following HCV treatment
with ribavirin. It has been shown that significant teratogenic and/or
embryocidal effects occurred in all animal species exposed to ribavirin; there
are no data to determine if this is also the case in humans. However, ribavirin
has been given an FDA Pregnancy Category X, indicating that it should not be
used in women who are pregnant.
The registry will accept reports of pregnancy exposures to ribavirin from
healthcare professionals, pregnant patients, or pregnant patients' male sexual
partners. Exposures of interest to the registry are those occurring during
pregnancy or up to six months before conception. For more information, go to:
http://www.ribavirinpregnancyregistry.com/index.htm
----------------------------------------------------------------
Return to top
(3 of 9)
December 2, 2005
MULTI-CENTER TREATMENT TRIAL FOR CHILDREN WITH CHRONIC HCV NOW ENROLLING
PATIENTS
PEDS C is a multi-center antiviral treatment trial for children with chronic
hepatitis C, ages 5–18 years. The purpose of the trial is to determine if
pegylated interferon alone will be as effective as pegylated interferon plus
ribavirin. The basis for this study design is that children respond well to
inteferon-based therapy alone and ribavirn may cause birth defects. In addition
to looking at response to therapy, the study will also investigate the effect of
therapy on body composition and growth and health-related quality of life.
Eleven centers in the United States are currently enrolling patients. Please
check the following websites for details and contact information:
http://www.PEDSC.org and
http://www.clinicaltrials.gov (type
in Pediatric HCV.)
----------------------------------------------------------------
Return to top
(4 of 9)
December 2, 2005
IAC REVISES MANY PRINT PIECES
IAC recently revised a dozen print pieces in response to the votes ACIP members
took at their meeting in October and new FDA vaccine approvals.
Updated pieces include the following:
- Summary of Recommendations for Childhood and
Adolescent Immunization
- Screening Questionnaire for Child and Teen
Immunization
- Screening Questionnaire for Adult Immunization
- Screening Questionnaire for Intranasal
Influenza Vaccination
- Notification of Vaccination Letter
- Temperature Log for Vaccines (Fahrenheit)
- Temperature Log for Vaccines (Celsius)
- Administering Vaccines: Dose, Route, Site, and
Needle Size
- Vaccines and Related Products Distributed in
the United States
- Interim VIS for meningococcal vaccine (dated
10/7/05) in Turkish
- September 2005 version of the Summary of
Recommendations for Childhood and Adolescent Immunization in Turkish
- Should You be Tested for Hepatitis C? A
Screening Questionnaire for Adults in Turkish
(1) Summary of Recommendations for Childhood and
Adolescent Immunization (three pages) has updated information about
tetanus-diphtheria-acellular-pertussis vaccine (Tdap) and hepatitis A vaccine.
To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/rules1.pdf
To access a web-text (HTML) version, go to:
http://www.immunize.org/nslt.d/n17/rules1.htm
(2) Screening Questionnaire for Child and Teen Immunization (two pages) has
updated information on three vaccines that protect against tetanus, diphtheria,
and pertussis (DTP, DTaP, Tdap) and on intranasal live attenuated influenza
vaccine (LAIV). In addition, the introduction was changed.
To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/p4060scr.pdf
To access a web-text (HTML) version, go to:
http://www.immunize.org/catg.d/p4060scr.htm
(3) Screening Questionnaire for Adult Immunization (two pages) has updated
information on intranasal live attenuated influenza vaccine (LAIV). Also, the
introduction was changed.
To access a ready-to-print (PDF) version of it,
go to:
http://www.immunize.org/catg.d/p4065scr.pdf
To access a web-text (HTML) version, go to:
http://www.immunize.org/catg.d/p4065scr.htm
(4) Screening Questionnaire for Intranasal Influenza Vaccination (two pages) has
updated information on intranasal live attenuated influenza vaccine (LAIV).
Also, the introduction was changed.
To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/p4067.pdf
To access a web-text (HTML) version, go to:
http://www.immunize.org/catg.d/p4067.htm
(5) Notification of Vaccination Letter (one page) has updated information on
tetanus-diphtheria-acellular pertussis vaccine (Tdap),
measles-mumps-rubella-varicella vaccine (MMRV), and intranasal live attenuated
influenza vaccine (LAIV). In addition, the document was completely reformatted.
To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/p3060not.pdf
No web-text (HTML) version is available.
(6) Minor changes were made to the Temperature Log for Vaccines (Fahrenheit;
four pages).
To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/p3039.pdf
No web-text (HTML) version is available.
(7) Minor changes were made to the Temperature Log for Vaccines (Celsius; four
pages).
To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/news.d/celsius.pdf
No web-text (HTML) version is available.
(8) Administering Vaccines: Dose, Route, Site, and Needle Size now includes
information about ProQuad, the newly licensed measles-mumps-rubella-varicella
vaccine.
To access a ready-to-print (PDF) version of it, go to:
http://www.immunize.org/catg.d/p3085.pdf
To access a web-text (HTML) version, go to:
http://www.immunize.org/catg.d/p3085.htm
(9) Vaccines and Related Products Distributed in the United States has been
updated with current information on all vaccines and biologics distributed in
the United States.
To access a ready-to-print (PDF) version of it,
go to:
http://www.immunize.org/catg.d/2019prod.pdf
No web-text (HTML) version is available.
(10) Interim VIS for meningococcal vaccine (dated 10/7/05) in Turkish
To access a ready-to-print (PDF) version of the interim VIS for meningococcal
vaccine in Turkish (dated 10/7/05), go to:
http://www.immunize.org/vis/tu_men05.pdf
To access a ready-to-print (PDF) version of it in English, go
to:
http://www.immunize.org/vis/menin05.pdf
For information about the use of VISs, and for VISs in a total of 33 languages,
visit IAC's VIS web section at
http://www.immunize.org/vis
(11) September 2005 version of the Summary of Recommendations for Childhood and
Adolescent Immunization in Turkish
Note: The current English-language version of the summary is dated November
2005. The most recent Turkish-language version is not current; the information
it contains was updated in September 2005.
To access a ready-to-print (PDF) version of the Summary of Recommendations for
Childhood and Adolescent Immunization in Turkish, go to:
http://www.immunize.org/catg.d/p2010tu.pdf
No web-text (HTML) version is available in Turkish.
To access a ready-to-print (PDF) version of the summary in English (dated
11/05), go to:
http://www.immunize.org/catg.d/rules1.pdf
To access a web-text (HTML) version of it in English, go to:
http://www.immunize.org/nslt.d/n17/rules1.htm
(12) Should You be Tested for Hepatitis C? A Screening Questionnaire for Adults
in Turkish
To access a ready-to-print (PDF) version of the questionnaire in Turkish (dated
10/05), go to:
http://www.immunize.org/catg.d/p2192tu.pdf
No web-text (HTML) version is available in Turkish.
To access a ready-to-print (PDF) version of the questionnaire in English (dated
10/05), go to:
http://www.immunize.org/catg.d/2192hepc.pdf
To access a web-text (HTML) version of it, go to:
http://www.immunize.org/catg.d/2192hepc.htm
---------------------------------------------------------------
Return to top
(5 of 9)
December 2, 2005
NEW: IAC WEBSITE PRESENTS STANDING ORDERS PROTOCOLS IN A SINGLE TABLE FOR EASY
REFERENCE
[The following is cross posted from the Immunization Action Coalition's "IAC
EXPRESS" electronic newsletter, 11/28/05.]
IAC recently organized links to all its standing orders protocols into one
table. The table gives website users easy access to the standing orders.
The table includes links to standing orders for administering the following
vaccines to adults: influenza, pneumococcal, hepatitis B, hepatitis A,
tetanus-diphtheria, measles-mumps-rubella, varicella, and meningococcal. It also
includes links to a protocol for medical management of vaccine reactions in
adults.
In addition, the table includes a standing orders protocol for administering
influenza vaccine to children and adolescents.
To access the table, go to:
http://www.immunize.org/standingorders
You can also access the table from IAC's homepage by going to
http://www.immunize.org and scrolling down
the Favorites listing in the left column until you reach the entry for standing
orders.
----------------------------------------------------------------
Return to top
(6 of 9)
December 2, 2005
CDC'S SATELLITE BROADCAST/WEBCAST ON SURVEILLANCE OF VACCINE-PREVENTABLE
DISEASES IS SET FOR DECEMBER 8
[The following is cross posted from the Immunization Action Coalition's "IAC
EXPRESS" electronic newsletter, 11/14/05.]
The CDC course Surveillance of Vaccine-Preventable Diseases will be broadcast
and webcast on December 8 from 12 noon to 3:30PM ET. The course is intended only
for public health professionals with responsibility for surveillance and case
investigation of vaccine-preventable diseases. Individual registration will
begin November 17.
Faculty includes William Atkinson, MD, MPH; John Moran, MD, MPH; Jane Seward,
MBBS, MPH; and Sandra Roush, MPH. All are with NIP/CDC. A live Q&A session will
allow participants nationwide to interact with course instructors by phone, fax,
and email.
For comprehensive course information, go to:
http://www.phppo.cdc.gov/PHTN/VPD-05 Questions about the course are being
taken by email at nipinfo@cdc.gov
To register online, go to:
http://www2a.cdc.gov/phtnonline Registration questions are being taken by
phone at (800) 418-7246 and by email at ce@cdc.gov
---------------------------------------------------------------
Return to top
(7 of 9)
December 2, 2005
NEW: PREPUBLICATION COPIES OF THE NINTH EDITION OF THE PINK BOOK NOW AVAILABLE
FOR ORDER
[The following is cross posted from the Immunization Action Coalition's "IAC
EXPRESS" electronic newsletter, 11/14/05.]
The ninth edition of the Pink Book (officially titled Epidemiology and
Prevention of Vaccine-Preventable Diseases) will be available February 2006. The
price is $25 for prepublication orders received by January 8, 2006. After
January 8, the price increases to $29.
The Pink Book is developed and published by NIP/CDC and distributed by the
Public Health Foundation. It provides physicians, nurses, pharmacists, and other
public health and healthcare professionals with comprehensive vaccine
information and recommendations, including the following:
- General recommendations on immunizations
including timing and spacing of vaccines
- Screening for contraindications and
precautions such as pregnancy and HIV infection
- Specific strategies to achieve high vaccine
coverage
- Vaccine safety information
Information on the following is included in the
ninth edition:
- Pertussis (to reflect licensure of Tdap
vaccine [tetanus-diphtheria-acellular pertussis] and recommendations for its
use)
- Meningococcal (to reflect licensure of
conjugate vaccine and recommendations for its use)
- Hepatitis A (to reflect the universal
recommendation for children 12-23 months and reduction of the minimum age from
two years to 12 months).
- Measles, mumps, rubella, and varicella (to
reflect the licensure of MMRV vaccine [measles-mumps-rubella-varicella])
For additional information about the Pink Book
and to order the ninth edition online, go to:
http://bookstore.phf.org/prod463.htm You can also order by calling (877)
252-1200.
--------------------------------------------------------------
Return to top
(8 of 9)
December 2, 2005
NEW: IAC WEBSITE CONSOLIDATES ANSWERS TO FAQs ONTO ONE WEB SECTION
[The following is cross posted from the Immunization Action Coalition's "IAC
EXPRESS" electronic newsletter, 11/28/05.]
To save you time, and the price of a long-distance phone call, IAC recently
gathered answers to questions you ask us most frequently and posted them in one
section of its main website.
To access the FAQ section, go to:
http://www.immunize.org/faq
You can also access the FAQ section from IAC's homepage by going to
http://www.immunize.org and scrolling down
the Favorites listing in the left column until you reach the entry for
frequently asked questions.
-------------------------------------------------------------
Return to top
(9 of 9)
December 2, 2005
TELECONFERENCE ABOUT IMMUNIZING MIGRANT WORKERS SCHEDULED FOR DECEMBER 13
[The following is cross posted from the Immunization Action Coalition's "IAC
EXPRESS" electronic newsletter, 11/28/05.]
The National Immunization Coalition TA [technical assistance] Network has
scheduled a teleconference that will focus on immunization outreach to migrant,
mobile, and immigrant communities. It will be held at 1:00PM, EDT, December 13.
NOTE: CDC will give updates on the current influenza vaccine supply at the
beginning of this teleconference and at the beginning of future teleconferences
throughout the influenza season.
The presenter is pediatrician Jennie McLaurin, MD, MPH. Trained in maternal and
child health care, Dr. McLaurin has 20 years' experience in migrant health care,
including service as an outreach worker, medical director, liaison with AAP, and
faculty member for the Health Disparities Collaboratives.
To register for the teleconference, email
IZTA@aed.org and put this message in the subject line: "Sign me up for
migrant health."
For additional information, or to access earlier programs, go to:
http://www.izcoalitionsta.org/confcall.cfm
|
Home
